Overview

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or in combination with capecitabine.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Treatments:
Capecitabine
Docetaxel
Gemcitabine
Vinorelbine